Prosecution Insights
Last updated: April 19, 2026
Application No. 18/276,346

LIQUID 1,3-DIOXOLANE COPOLYMERS

Non-Final OA §112
Filed
Aug 08, 2023
Examiner
SERGENT, RABON A
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Wacker Chemie AG
OA Round
1 (Non-Final)
54%
Grant Probability
Moderate
1-2
OA Rounds
3y 5m
To Grant
79%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allow Rate
525 granted / 970 resolved
-10.9% vs TC avg
Strong +25% interview lift
Without
With
+24.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
53 currently pending
Career history
1023
Total Applications
across all art units

Statute-Specific Performance

§101
0.2%
-39.8% vs TC avg
§103
52.8%
+12.8% vs TC avg
§102
8.0%
-32.0% vs TC avg
§112
19.5%
-20.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 970 resolved cases

Office Action

§112
Detailed Office Action Notice of Pre-AIA or AIA Status 1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objection 2. Objection is made to claim 9 in view of the use of the language “comprising: wherein …”, because the language is awkward and not of proper grammatical form. Claim Rejections - 35 USC § 112 3. The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. 4. Claims 14-16 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The examiner has reviewed WO 2022/174895 A1, this document having been published from PCT/EP2021/053905, which is the application from which the instant application is a national stage entry (35 USC 371), and has not found support for new claims 14-16. As drafted, claim 14 is drawn to the copolymerization of the 1,3-dioxolane copolymers with alkyl substituted 1,3-dioxolane; however, this has not been disclosed by applicants within the originally filed application. This subject matter is distinctly different from original claim 6. 5. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. 6. Claims 9-16 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Firstly, with respect to claims 9, 11, and 14, it is unclear how to precisely interpret the multiple uses of the language, “in each case”. Secondly, with respect to claims 9 and 14, applicants have failed to adequately define the x1, x2, y1, and y2 variables. As drafted, it is unclear if x1+x2 and y1+y2 mandates the presence and/or specifies the number of each segment governed by the single variable. Furthermore, the variable y1+y2 is defined by referencing itself; such a definition precludes conclusively calculating the value of each variable, without additional information, which has not been claimed. With respect to claim 13, the language, “the graphical evaluation”, lacks antecedence. Allowable Subject Matter 7. Claims 9-13 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), 2nd paragraph, set forth in this Office action. 8. Claim 9-13 are allowable over the prior art of record, the most relevant of which is the non-patent literature reference to Goulart et al. While the reference discloses copolymers of 1,3-dioxolane and 4-methyl-1,3-dioxolane, there is insufficient disclosure establishing the that terminal groups of the disclosed polymers encompass hydroxyl groups, as instantly claimed. Conclusion 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rabon A Sergent whose telephone number is (571)272-1079. The examiner can normally be reached on Monday through Friday from 9:00 AM until 5:00 PM, ET. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Riviere Kelley, can be reached at telephone number 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center to authorized users only. Should you have questions about access to the USPTO patent electronic filing system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via a variety of formats. See MPEP § 713.01. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/InterviewPractice. /RABON A SERGENT/ Primary Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Aug 08, 2023
Application Filed
Dec 27, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12589153
POLYURETHANE EXCIPIENT
2y 5m to grant Granted Mar 31, 2026
Patent 12583964
POLYTHIOL COMPOSITION, POLYMERIZABLE COMPOSITION, RESIN, MOLDED ARTICLE, OPTICAL MATERIAL, AND LENS
2y 5m to grant Granted Mar 24, 2026
Patent 12570785
THERMOPLASTIC POLYURETHANE RESIN ELASTOMERS
2y 5m to grant Granted Mar 10, 2026
Patent 12559586
COMPOSITIONS CONTAINING URETDIONE GROUPS CROSSLINKING AT LOW TEMPERATURES
2y 5m to grant Granted Feb 24, 2026
Patent 12545760
URETHANE RESIN COMPOSITION, FILM, AND SYNTHETIC LEATHER
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
54%
Grant Probability
79%
With Interview (+24.8%)
3y 5m
Median Time to Grant
Low
PTA Risk
Based on 970 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month